Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Min He
Institution:
Boehringer Ingelheim (United States)
Observed institution:
Boehringer Ingelheim (United States)
ORCID:
0009-0002-2334-8512
Observed ORCID:
0009-0002-2334-8512
OpenAlex ID:
A5133786085
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
·
Cancer Research Communications
·
5
PDF
Table 4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Data from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Supplementary Materials from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table 3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S6 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table 2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure S3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure 2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure S2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure S4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table 5 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Figure 3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Table S5 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026
·
James J. Harding
, Ralf Hofheinz
, et al.
Show more works
View as search
Works count:
21
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type